Clinical studies have revealed high expression of GSNOR in the airways and pulmonary vasculature of BPD patients (117), suggesting its significance in BPD pathogenesis and its potential as a therapeutic target for BPD-PH. This evidence concerns the gene ADH5 and bronchopulmonary dysplasia.